“For decades, our biomedical research system has relied heavily on animal models. With this initiative, NIH is ushering in a new era of innovation,” said NIH Director Dr. Jay Bhattacharya.
The initiative will focus on advancing cutting-edge technologies such as organoids, tissue chips, and other in vitro systems that more accurately model human biology, capture individual variability, and reflect patient-specific characteristics.
VITROCELL in vitro exposure systems are already widely adopted for inhalation research, enabling scientists to assess the effects of gases, complex mixtures, nanoparticles, fibers, and dry powders at the air-liquid interface.
In partnership with AlveoliX , we offer state-of-the-art exposure solutions for the breathing lung-on-chip AlveoliX AX12 – supporting this shift toward more human-relevant research.
Read the full NIH press release
here. 
